Volasertib
- Generic Name
- Volasertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C34H50N8O3
- CAS Number
- 755038-65-4
- Unique Ingredient Identifier
- 6EM57086EA
- Background
Volasertib has been used in trials studying the treatment of Leukemia, Neoplasms, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, and Leukemia, Monocytic, Acute, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML
- Conditions
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT01957644
- Locations
- 🇫🇷
1230.33.33002 Boehringer Ingelheim Investigational Site, Marseille, France
🇫🇷1230.33.33001 Boehringer Ingelheim Investigational Site, Paris, France
🇩🇪1230.33.49002 Boehringer Ingelheim Investigational Site, Dresden, Germany
Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT01772563
- Locations
- ðŸ‡ðŸ‡º
National Institute of Oncology, Budapest, Hungary
ðŸ‡ðŸ‡ºPRA Hungary Ltd., Phase I. Clinical Pharmacology Unit, Budapest, Hungary
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
- Conditions
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 666
- Registration Number
- NCT01721876
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇫🇷HOP Côte de Nacre, Caen, France
🇫🇷HOP Haut-Lévêque, Pessac, France
Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT01662505
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Yoshida-gun, Fukui, Japan
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 180
- Registration Number
- NCT00804856
- Locations
- 🇫🇷
HOP Edouard Herriot, Lyon Cedex 03, France
🇨🇦Montreal General Hospital - McGill University Health Centre, Montreal, Quebec, Canada
🇫🇷HOP Clémenceau, Hémato, Caen, Caen, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.